Literature DB >> 34799724

METTL3-mediated N6-methyladenosine modification of DUSP5 mRNA promotes gallbladder-cancer progression.

Hua-Dong Chen1, Fuxi Li2, Siyun Chen3, Zhi-Hai Zhong1, Peng-Fei Gao1, Wen-Zong Gao4.   

Abstract

N6-methyladenosine (m6A) RNA methylation and its associated methyltransferase METTL3 play an important role in tumorigenesis of a series of tumors. However, dysregulation of METTL3 in gallbladder cancer (GBC) remains obscure. Here, we showed that upregulated METTL3 level predicted poor prognosis and correlated with increased lymphatic metastasis and high TNM stage. Functionally, we found that METTL3 could promote cell proliferation, invasion, and migration of GBC-SD and NOZ cells. Mechanistically, we revealed the METTL3-mediated m6A-modification profile in GBC cells and identified DUSP5 as the downstream gene of METTL3. METTL3 promoted the degradation of DUSP5 mRNA in a YTHDF2-dependent manner. Rescue assays showed that downregulation of DUSP5 could attenuate the knockdown METTL3-mediated inhibition of cell proliferation, invasion, and migration of GBC-SD and NOZ cells. Thus, our finding shows that elevated METTL3 expression contributes to tumor aggression in GBC, suggesting that METTL3 is a possible prognostic predictor and therapeutic target against GBC.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34799724     DOI: 10.1038/s41417-021-00406-5

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  1 in total

1.  Dual-specificity phosphatase 5 suppresses ovarian cancer progression by inhibiting IL-33 signaling.

Authors:  Li Wang; Jinghui Hu; Dongmei Qiu; Hongyan Gao; Wei Zhao; Yujie Huang; Tingting Jiang; Jinhua Zhou; Youguo Chen
Journal:  Am J Transl Res       Date:  2019-02-15       Impact factor: 4.060

  1 in total
  1 in total

1.  ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators.

Authors:  Zhonglin Cai; Huan Xu; Gang Bai; Hanjing Hu; Di Wang; Hongjun Li; Zhong Wang
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.